Bausch Health Companies Inc.BHC

NYSEHealthcarePharmaceutical Preparations
Price (close)
$5.69
Market cap
$2.1B
P/E
—
Revenue (TTM)
$10.9B
Net income
-$1.1B
Dividend yield
—
1-year total return
-11.9%
Net margin
-10.1%
Revenue growth
10.1%
Debt / equity
—

What Bausch Health Companies Inc. does.

Bausch Health Companies Inc. (“we”, “us”, “our”, the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company’s products are marketed directly or indirectly in approximately 90 countries.

Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb. The following is a brief description of the Company’s segments:

• The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan ® product line currently represent approximately 85% of the Salix segment revenues.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$8.0B$8.4B$8.1B$8.8B$9.6B$10.3B
Net income-$560.0M-$948.0M-$225.0M-$592.0M-$46.0M$157.0M
Free cash flow$809.0M$1.2B-$946.0M$817.0M$1.3B$1.0B

More on BHC.

Figures from Bausch Health Companies Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.